Ophthalmic Drugs Market Summary

The global ophthalmic drugs market size was estimated at USD 38.20 billion in 2024 and is projected to reach USD 62.08 billion by 2030, growing at a CAGR of 8.5% from 2025 to 2030. The market growth is attributed to rising eye disease prevalence, advancement in drug delivery, and an increasing focus on research for the development of novel therapeutics in the market. The growing elderly population, higher screen-time exposure, and lifestyle-related disorders are also contributing to the higher incidence of vision impairment and ocular conditions worldwide, supporting demand for effective ophthalmic drugs.

Moreover, increasing investment by public and private organizations is further propelling the growth of the market. For instance, in July 2023, the National Eye Institute announced a funding of USD 2.5 million for over 5 years to advance the glaucoma treatment research at Missouri University of Science and Technology. Continuous innovation in sustained-release formulations, biologics, and gene-based therapies is expected to create better patient outcomes and further accelerate product adoption.

Key Market Trends & Insights

  • North America ophthalmic drugs market dominated the global market and accounted for a 42.7% share in 2024. Factors such as improved access to advanced ophthalmic care, a strong presence of leading manufacturers, and rising awareness for early diagnosis contribute to regional leadership.
  • The ophthalmic drugs market in the U.S. is expected to witness significant growth over the forecast period due to increasing cases of chronic eye diseases including glaucoma, diabetic retinopathy, and age-related macular degeneration, along with strong research capabilities and regulatory support for innovative therapies.
  • By disease, retinal disorders led the market in 2024 and are anticipated to grow at the fastest growth rate over the forecast period. Increasing prevalence of age-related macular degeneration and diabetic eye complications drives medication demand for retinal health.
  • By route of administration, the topical route of administration led the market in 2024, owing to better patient convenience, non-invasive nature, and wide availability of treatment options in liquid and semi-solid forms.
  • By dosage form, eye drops led the market in 2024 and are anticipated to grow at the fastest growth rate over the forecast period due to their ease of use, lower infection risk, and suitability for treating most common eye conditions.

Order a free sample PDF of the Ophthalmic Drugs Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

  • 2024 Market Size: USD 38.20 Billion
  • 2030 Projected Market Size: USD 62.08 Billion
  • CAGR (2025-2030): 8.5%
  • North America: Largest market in 2024

Key Companies & Market Share Insights

Some of the key players operating in the market include Alcon; Novartis AG; Bausch Health Companies, Inc.; Merck & Co., Inc.and others. The market is highly competitive, with a large number of manufacturers accounting for a majority of the share. New source developments, mergers and acquisitions, and collaborations are major strategies these players adopt to counter the high competition.

Key Players

  • Alcon
  • Novartis AG
  • Bausch Health Companies, Inc.
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Coherus BioSciences, Inc.
  • AbbVie, Inc. (Allergan)
  • Pfizer, Inc.
  • Bayer AG
  • Santen Pharmaceutical Co., Ltd.
  • Roche (Genentech, Inc.)
  • Nicox

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The ophthalmic drugs market is poised for robust growth as global eye disease burden continues to rise and demand for innovative vision-preserving treatments increases. Technological advancements in drug delivery, including sustained-release and targeted therapies, are improving patient adherence and treatment effectiveness. Supportive funding from public and private bodies for ocular research is accelerating the development of next-generation therapeutics. With North America continuing to lead, expanding healthcare access and growing awareness in emerging regions are also boosting market penetration. As companies focus on biologics and gene-based solutions, the market is expected to play a critical role in reducing vision impairment and improving quality of life worldwide.